News

News

BioTek Receives Patent for Automated Media Exchange (AMX) Module for the MultiFlo FX Multi-Mode Dispenser

January 28, 2021

BioTek Instruments, an Agilent Technologies, Inc., company, announces that it was granted a patent by the United States Patent and Trademark Office for the Automated Media Exchange (AMX) module for  the MultiFlo FX Multi-Mode Dispenser. In cell biology workflows, the automated MultiFlo FX with AMX module enables hands-free, gentle, and highly consistent media exchanges and washing in 96- and 384-well microplate formats without disturbing sensitive cells. This promotes viability and long-term differentiation in 3-dimensional (3D) cell culture models as well as effective maintenance of loosely adherent 2-dimensional (2D) cell cultures.

The modular MultiFlo FX can incorporate up to four dispensers and a washer for flexibility with a wide variety of applications. The AMX module uses two software-controlled peristaltic pumps to control the media flow and adjustable x-y-z positioning of the specially designed, dedicated aspirate and dispense manifolds to avoid damage or unintentional removal of cells. The MultiFlo FX with AMX module may be integrated with BioTek’s automated incubator, imagers, or multi-mode readers to enhance walkaway convenience and efficiency.

BioTek Instruments, Inc., a part of Agilent and headquartered in Winooski, VT, USA, is a worldwide leader in the design, manufacture, and distribution of innovative life science instrumentation. Our comprehensive product line includes cell imaging systems, microplate readers, washers, dispensers, automated incubators and stackers. These products enable life science research by providing high performance, cost-effective analysis and quantification of biomolecules, biomolecular interactions and cellular structure and function across diverse applications. BioTek espouses a "Think Possible" approach that sets the tone for fresh ideas, unsurpassed customer service and original innovations.



For Research Use Only.  Not for use in diagnostic procedures.

For additional information, contact:

Chere Griffin
Expression Marcom, LLC
908-818-9463
cgriffin@expressionmarcom.com



 
link